New hope for aortic tear patients: common drug may cut surgery risks

NCT ID NCT06968806

Recruiting now Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a short course of the anti-inflammatory drug ketorolac to standard emergency surgery care can improve recovery for patients with a life-threatening tear in their main heart artery (Type A aortic dissection). 360 patients will be randomly assigned to receive either ketorolac or a placebo injection and pills for two days after their operation. Researchers will track serious complications, death rates, and signs of inflammation to see if the drug helps patients heal better.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210008, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AORTIC DISSECTION INFLAMMATION